MA39059A1 - Système d'administration de médicament. - Google Patents

Système d'administration de médicament.

Info

Publication number
MA39059A1
MA39059A1 MA39059A MA39059A MA39059A1 MA 39059 A1 MA39059 A1 MA 39059A1 MA 39059 A MA39059 A MA 39059A MA 39059 A MA39059 A MA 39059A MA 39059 A1 MA39059 A1 MA 39059A1
Authority
MA
Morocco
Prior art keywords
therapeutic agent
thermoplastic polymer
delivery system
drug delivery
core
Prior art date
Application number
MA39059A
Other languages
English (en)
Inventor
Willy J H Verhoeven
Graaff Wouter De
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA39059A1 publication Critical patent/MA39059A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système intravaginal d'administration de médicament comprenant (i) un noyau comprenant un premier polymère thermoplastique et un premier agent thérapeutique, le premier agent thérapeutique étant dissous dans le premier polymère thermoplastique et (ii) une pellicule entourant le noyau comprenant un deuxième polymère thermoplastique, le premier agent thérapeutique étant moins perméable dans le deuxième polymère thermoplastique que dans le premier polymère thermoplastique, et un deuxième agent thérapeutique sous forme solide, le deuxième agent thérapeutique étant chargé dans une partie de la pellicule.
MA39059A 2013-12-11 2014-12-08 Système d'administration de médicament. MA39059A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196737 2013-12-11
PCT/EP2014/076823 WO2015086491A1 (fr) 2013-12-11 2014-12-08 Système d'administration de médicament.

Publications (1)

Publication Number Publication Date
MA39059A1 true MA39059A1 (fr) 2018-08-31

Family

ID=49759119

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39059A MA39059A1 (fr) 2013-12-11 2014-12-08 Système d'administration de médicament.

Country Status (23)

Country Link
US (1) US10413504B2 (fr)
EP (1) EP3079660B1 (fr)
JP (1) JP6251396B2 (fr)
KR (1) KR101808977B1 (fr)
CN (1) CN105979930B (fr)
AP (1) AP2016009223A0 (fr)
AU (1) AU2014363724B2 (fr)
BR (1) BR112016013325B1 (fr)
CA (1) CA2931559C (fr)
CR (1) CR20160261A (fr)
DO (1) DOP2016000132A (fr)
EA (1) EA031802B1 (fr)
HK (1) HK1224208A1 (fr)
IL (1) IL245544A0 (fr)
MA (1) MA39059A1 (fr)
MD (1) MD20160079A2 (fr)
MX (1) MX2016007681A (fr)
PE (1) PE20160680A1 (fr)
PH (1) PH12016501083A1 (fr)
SG (1) SG11201604660VA (fr)
SV (1) SV2016005214A (fr)
TW (1) TW201607563A (fr)
WO (1) WO2015086491A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
EP3079659B1 (fr) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Système d'administration de médicaments pour la fourniture d'antiviraux
MX357743B (es) 2013-12-19 2018-07-23 Procter & Gamble Formacion de fibras de queratina con 2-hidroxipropano-1,2,3-acido tricarboxilico y/o 1,2,3,4-acido butanetetracarboxilico.
EP3082731B1 (fr) 2013-12-19 2018-07-04 The Procter and Gamble Company Façonnage de fibres de kératine utilisant un principe actif comprenant au moins deux groupes fonctionnels choisis entre -c(oh)- et -c(=o)oh
MX376963B (es) 2013-12-19 2025-03-07 Procter & Gamble Modelado de fibras de queratina mediante el uso de éster de carbonato.
JP6346951B2 (ja) 2013-12-19 2018-06-20 ザ プロクター アンド ギャンブル カンパニー ケラチン繊維の成形方法
MX2016008163A (es) 2013-12-19 2016-09-16 Procter & Gamble Formacion de fibras de queratina mediante el uso de una composicion reductora y una composicion fijadora.
CN105828787B (zh) 2013-12-19 2019-07-26 宝洁公司 使用氧代乙酸和/或它们的衍生物使角蛋白纤维成形
JP6385438B2 (ja) 2013-12-19 2018-09-05 ザ プロクター アンド ギャンブル カンパニー 糖類を使用したケラチン繊維の成形
EP3017809A1 (fr) * 2014-11-07 2016-05-11 Ferring B.V. Unité de dispositif de médicaments contenant de la quinagolide
MX2017008203A (es) 2014-12-19 2017-10-06 Procter & Gamble Metodo para dar forma a fibras de queratina.
WO2016100257A1 (fr) 2014-12-19 2016-06-23 The Procter & Gamble Company Modelage de fibres de kératine à l'aide d'arabinose et de carbonate d'éthylène
MX2017016152A (es) 2015-06-18 2018-04-18 Procter & Gamble Modelado de fibras de queratina mediante el uso de compuestos de dialdehido.
EP3334413B1 (fr) * 2015-08-11 2022-05-18 PTT Holding Aps Dispositif d'administration
EP3395335A1 (fr) * 2017-04-24 2018-10-31 Kern Pharma, S.L. Anneau vaginal pour la libération simultanée de deux principes actifs
DE102017113166A1 (de) * 2017-06-14 2018-12-20 Amw Gmbh Depotform zur Abgabe eines Östrogen-Wirkstoffs
KR20210013089A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
EP3803866A4 (fr) 2018-05-24 2022-03-16 Nureva Inc. Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones
KR20210013088A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4465939A4 (fr) * 2022-01-21 2026-01-07 The Population Council Inc Anneaux intravaginaux de thérapie combinée
EP4215180A1 (fr) * 2022-01-21 2023-07-26 Sever Pharma Solutions Système d'administration de médicaments
EP4626399A1 (fr) 2022-12-02 2025-10-08 VaRi Bioscience GmbH Anneau vaginal libérant de l'estriol

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
DE3571924D1 (en) 1984-04-11 1989-09-07 Thiemann Arzneimittel Gmbh Dosage units for controlled release of active material
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
EP0406315B1 (fr) 1988-03-24 1992-11-11 Bukh Meditec A/S Composition a diffusion regulee
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
WO1997002015A1 (fr) 1995-07-04 1997-01-23 Akzo Nobel N.V. Dispositifs annulaires
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
IL123813A0 (en) 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
JP2002508284A (ja) 1997-12-12 2002-03-19 アクゾ・ノベル・エヌ・ベー 膣内挿入リング用包装材料
BR9813740A (pt) 1997-12-18 2000-10-10 Lilly Co Eli Teriparatìdeo cristalino
US6579533B1 (en) 1999-11-30 2003-06-17 Bioasborbable Concepts, Ltd. Bioabsorbable drug delivery system for local treatment and prevention of infections
CN1536986B (zh) 2001-03-27 2012-07-04 沃纳奇尔科特(爱尔兰)有限公司 用于抗微生物剂给药的阴道内药物递送装置
WO2003000156A1 (fr) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
PL367961A1 (en) 2001-08-31 2005-03-07 Schering Oy Drug delivery system
WO2003026626A2 (fr) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Forme pharmaceutique a liberation modifiee
CN1242819C (zh) 2002-06-07 2006-02-22 上海市计划生育科学研究所 一种新型阴道环及制备方法
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
TWI336627B (en) * 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
ES2442675T3 (es) 2003-07-10 2014-02-12 Warner Chilcott (Ireland) Limited Dispositivos intravaginales de suministro de fármacos
WO2005030175A1 (fr) * 2003-09-29 2005-04-07 Novo Nordisk Femcare Ag Formulations hrt
JP2007530500A (ja) * 2004-03-24 2007-11-01 ナームローゼ・フエンノートチヤツプ・オルガノン ポリエチレン酢酸ビニル共重合体に基づく薬物送達システム
KR20060046263A (ko) * 2004-08-04 2006-05-17 도쿄파츠고교 가부시키가이샤 편평형 진동모터를 내장시킨 전자음향변환기
TW200727920A (en) 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
ES2425842T3 (es) * 2006-11-20 2013-10-17 Intervet International B.V. Sistema de administración de fármaco con forma helicoidal
US10258571B2 (en) 2007-02-12 2019-04-16 Particle Sciences, Inc. Delivery devices containing encapsulated and/or practice-bound active pharmaceutical ingredients
US20080242650A1 (en) 2007-03-26 2008-10-02 Jean-Louis Thomas Oral contraceptive regimen
ES2538838T3 (es) 2007-09-07 2015-06-24 Mati Therapeutics Inc. Método para preparar insertos de fármacos para liberación sostenida de agentes terapéuticos
US8741329B2 (en) 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
IN2012DN00711A (fr) * 2009-07-21 2015-06-19 Population Council Inc
EP2468750A1 (fr) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Formes polymorphiques de maléate d'asénapine et procédés de préparation
TW201332585A (zh) 2012-02-14 2013-08-16 Chemo Res S L 核鞘藥物遞送裝置
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
CR20160261A (es) 2016-08-16
KR101808977B1 (ko) 2017-12-13
EP3079660B1 (fr) 2021-03-03
US10413504B2 (en) 2019-09-17
CA2931559C (fr) 2018-03-13
JP6251396B2 (ja) 2017-12-20
SG11201604660VA (en) 2016-07-28
BR112016013325A2 (fr) 2017-08-08
EA201691193A1 (ru) 2016-09-30
CA2931559A1 (fr) 2015-06-18
HK1224208A1 (zh) 2017-08-18
WO2015086491A1 (fr) 2015-06-18
SV2016005214A (es) 2016-11-21
DOP2016000132A (es) 2016-07-31
TW201607563A (zh) 2016-03-01
IL245544A0 (en) 2016-06-30
CN105979930B (zh) 2019-11-19
JP2016539991A (ja) 2016-12-22
PH12016501083A1 (en) 2016-07-25
BR112016013325B1 (pt) 2022-11-29
EP3079660A1 (fr) 2016-10-19
AU2014363724A1 (en) 2016-05-26
CN105979930A (zh) 2016-09-28
AP2016009223A0 (en) 2016-05-31
AU2014363724B2 (en) 2017-02-23
PE20160680A1 (es) 2016-07-31
MX2016007681A (es) 2016-10-14
EA031802B1 (ru) 2019-02-28
MD20160079A2 (ro) 2016-10-31
US20150157561A1 (en) 2015-06-11
KR20160095110A (ko) 2016-08-10

Similar Documents

Publication Publication Date Title
MA39059A1 (fr) Système d'administration de médicament.
BR112012027442B1 (pt) sistema de distribuição de solução iv para distribuição intravenosa de uma solução perigosa e método para fabricação de um dispositivo de filtro de droga perigosa para uso em combinação com um sistema de distribuição intravenosa
WO2009105432A3 (fr) Dispositifs et procédés pour l'administration d'un agent thérapeutique à travers une pneumostomie
BR112015022433A2 (pt) dispositivos de liberação de droga com componente permeável à droga e métodos
BR112012027441A2 (pt) sistemas e métodos para fornecimento de um conjunto iv de droga perigosa de ventilação fechada
CL2017002652A1 (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112015022055A2 (pt) gestão de transições de área de cuidado de infusões intravenosas
BRPI0714399B8 (pt) composição farmacêutica líquida oral
EP2349406A4 (fr) Système de régulation automatique et procédé de régulation d'une anesthésie
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
EP2589379A4 (fr) Système transdermique d'administration de médicament contenant du donépézil
MX381625B (es) Administración y monitoreo de óxido nítrico en fluidos ex vivo.
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
EA201000747A1 (ru) Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки
MX352326B (es) Tableta resistente al alcohol.
EP2004172A4 (fr) Méthodes d'administration de médicaments, structures et compositions utilisées dans le système nasolacrymal
BR112014027039A2 (pt) formulação farmacêutica tópica não aquosa; uso de formulação farmacêutica não aquosa; formulação não aquosa; e método
ECSP10010399A (es) Sistema de administración de drogas con efecto estabilizante
UY31975A (es) Sistema y administración transdérmica de estrógeno
MX2021003633A (es) Dispositivo de depósito biodegradable subcutáneo.
MX2021011295A (es) Sistemas y metodos para suministrar agentes activos.
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação